Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 998 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cream Clear all
Completed Phase 1 Interventional

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Anaheim, California • Encino, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

NCT07146971
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
OTC Drug for Atopic Dermatitis in Cream form
Drug
Lead sponsor
Good Molecules, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

NCT03892564
View directory record Official record
Conditions
Phototoxicity
Interventions
MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Results available

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

NCT06336603
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% & Adapalene 0.3% gel
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Results available

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

NCT01958073
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Conjugated Estrogen Vaginal Cream, Estradiol Ring, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

NCT01369303
View directory record Official record
Conditions
Prevention
Interventions
Tenofovir 1% vaginal gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 23, 2026, 4:46 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Topical CBD for Musculoskeletal Pain

NCT05170451
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
CBD, Control
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)

NCT04531540
View directory record Official record
Conditions
Hypersensitivity
Interventions
Butenafine HCl 1% (BAY1896425)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06959225
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
59
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

NCT02770365
View directory record Official record
Conditions
Atrophy
Interventions
estrace cream (Perrigo), estrace cream (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 4 Interventional

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

NCT01202149
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
Device
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®

NCT00742183
View directory record Official record
Conditions
Second Degree Burn
Interventions
Mepilex, Silvadene
Device
Lead sponsor
Molnlycke Health Care AB
Industry
Eligibility
5 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

NCT01813162
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% gel, Vaginal product
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
San Francisco, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

NCT01171469
View directory record Official record
Conditions
Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma, Anaplastic Astrocytoma
Interventions
Dendritic Cells, Imiquimod
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Duration of Skin Numbing Effect Created by the S-Caine™ Peel

NCT00110253
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)

NCT00652080
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
API 31510
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Hot Springs, Arkansas • San Diego, California • Buffalo Grove, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

NCT04203342
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Drug
Lead sponsor
Douglas Pharmaceuticals America Ltd
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Brandon, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Early Phase 1 Interventional Results available

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

NCT01398280
View directory record Official record
Conditions
Rosacea
Interventions
Topical aminocaproic acid (ACA) mixed with Vanicream, Vehicle cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Phase 1 Interventional

A Novel Treatment for Metastatic Melanoma

NCT00758797
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Photoimmunotherapy
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Phase 2 Interventional Results available

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

NCT00799110
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1

NCT01811329
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Dairy fat, Dairy fat + MFGM, Palm fat, Palm fat + MFGM
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skin Prick Test of KeraStat® Cream

NCT04058054
View directory record Official record
Conditions
Hypersensitivity
Interventions
KeraStat® Cream, KeraStat Gel, Biafine, Histamine, Saline (0.9% NaCl)
Device · Drug
Lead sponsor
KeraNetics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 23, 2026, 4:46 PM EDT